“Impella secured approval in Japan; the late summer approval was largely on target. The label is somewhat different than in the US: Impella is indicated for drug-resistant acute heart failure, but not prophylactic or elective use.”,” Jefferies Group’s analyst commented.
Other equities research analysts have also recently issued reports about the stock. Goldman Sachs Group Inc. reissued a buy rating and issued a $202.00 price target on shares of Amgen in a research report on Wednesday, June 15th. Vetr raised shares of Amgen from a hold rating to a buy rating and set a $159.50 price target for the company in a research report on Monday, June 13th. Zacks Investment Research raised shares of Amgen from a hold rating to a buy rating and set a $166.00 price target for the company in a research report on Wednesday, June 29th. BMO Capital Markets reissued a buy rating and issued a $186.00 price target on shares of Amgen in a research report on Tuesday, July 12th. Finally, Credit Suisse Group AG reaffirmed a buy rating and issued a $206.00 target price on shares of Amgen in a report on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $184.51.
Amgen (NASDAQ:AMGN) traded down 0.658% during midday trading on Wednesday, reaching $168.593. The company had a trading volume of 471,209 shares. The firm’s 50 day moving average is $172.00 and its 200 day moving average is $160.83. Amgen has a 1-year low of $135.64 and a 1-year high of $176.85. The stock has a market capitalization of $126.17 billion, a PE ratio of 17.253 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period in the previous year, the company earned $2.57 earnings per share. Amgen’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, equities analysts anticipate that Amgen will post $11.36 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were given a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.36%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Valley National Advisers Inc. increased its position in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock worth $109,000 after buying an additional 33 shares in the last quarter. Glassman Wealth Services increased its position in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares in the last quarter. Oakworth Capital Inc. increased its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Integrated Wealth Management increased its position in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Finally, Delta Asset Management LLC TN increased its position in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.